

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : WALKER et al.
Serial No. : To Be Assigned
For : REGULATION OF INTRACELLULAR
GLUCOCORTICOID CONCENTRATIONS
Filed : Concurrently Herewith
Examiner : To Be Assigned
Art Unit : To Be Assigned


745 Fifth Avenue, New York, NY 10151


EXPRESS MAIL

Mailing Label Number: EV 073646223 US

Date of Deposit: February 22, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, DC 20231.


(Typed or printed name of person mailing paper or fee)


(Signature of person mailing paper or fee)

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231
Box Patent Application

Dear Sir:

Prior to examination, please amend the above-referenced application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

IN THE SPECIFICATION:

Page 1, before the first paragraph, please insert thereat:

--REFERENCE TO RELATED APPLICATIONS

This application is a divisional application of allowed U.S. Application Serial No. 09/029,535, filed February 27, 1998, which is the National Stage application of international application PCT/GB96/02134 filed August 28, 1996, published as WO 97/07789 on March 6, 1997, and claims priority from British Application 9517622.8 filed August 29, 1995. Reference is made to U.S. Application Serial No. 10/061,044 filed January 30, 2002 as a divisional application of U.S. Application Serial No. 09/029,535. Reference is also made to four additional applications, also filed as divisional applications of U.S. Application Serial No. 09/029,535 on February 22, 2002, application numbers to be assigned, (Attorney docket numbers 674543-2001.2, 674543-2001.3, 674543-2001.4 and 674543-2001.5).

The above-mentioned applications, as well as all documents cited herein and documents referenced or cited in documents cited herein, are hereby incorporated herein by reference.--

IN THE CLAIMS:

Kindly cancel claims 1-13, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.

Kindly add new claims 14-22, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents:

--14. (New) A method for reducing circulating fatty acids from, or maintained by, reductase activity of 11-Beta-hydroxysteroid dehydrogenase 1 (11-Beta HSD1) in adipose tissue in a patient in need thereof comprising

determining reductase activity of 11 Beta HSD1 in adipose tissue, and

inhibiting said reductase activity of 11-Beta HSD1 in adipose tissue in said patient.

15. (New) A method for reducing circulating fatty acids from, or maintained by, reductase activity of 11-Beta-hydroxysteroid dehydrogenase 1 (11-Beta HSD1) in adipose tissue in a patient in need thereof comprising

determining reductase activity of 11 Beta HSD1 in adipose tissue,

determining whether a compound or composition inhibits said reductase activity of 11

Beta HSD1 in adipose tissue, and

administering to said patient said compound or composition which inhibits said reductase activity of 11-Beta HSD1 in adipose tissue, in an amount effective to so inhibit said reductase activity of 11-Beta HSD1 in adipose tissue.

16. (New) The method of claim 14 wherein the inhibiting is by administering carbenoxolone or a pharmaceutically acceptable salt thereof.
17. (New) The method of claim 15, wherein determining whether a compound or composition inhibits said reductase activity of 11-Beta HSD1 in adipose tissue comprises:
obtaining reductase activity of 11-Beta HSD1 in an isolated *in vitro* adipocyte cell population, and
contacting said compound or composition with said adipocyte cell population.
18. (New) The method of claim 15 wherein the compound or composition which inhibits said reductase activity of 11-Beta HSD1 in adipose tissue is carbenoxolone or a pharmaceutically acceptable salt thereof.
19. (New) The method of claim 14, wherein said patient suffers from one of the following: obesity, insulin resistance, or obesity and insulin resistance.
20. (New) The method of claim 15; wherein said patient suffers from one of the following: obesity, insulin resistance, or obesity and insulin resistance.
21. (New) A method for treating obesity, insulin resistance, or obesity and insulin resistance by regulating reductase activity of 11-Beta-hydroxysteroid dehydrogenase 1 (11-Beta HSD1) in adipose tissue in a patient in need thereof comprising
determining reductase activity of 11 Beta HSD1 in adipose tissue, and
inhibiting said reductase activity of 11-Beta HSD1 in adipose tissue in said patient.
22. (New) A for treating obesity, insulin resistance, or obesity and insulin resistance by regulating reductase activity of 11-Beta-hydroxysteroid dehydrogenase 1 (11-Beta HSD1) in adipose tissue in a patient in need thereof comprising
determining reductase activity of 11 Beta HSD1 in adipose tissue,
determining whether a compound or composition inhibits said reductase activity of 11 Beta HSD1 in adipose tissue, and
administering to said patient said compound or composition which inhibits said reductase activity of 11-Beta HSD1 in adipose tissue, in an amount effective to so inhibit said reductase activity of 11-Beta HSD1 in adipose tissue.--

IN THE ABSTRACT:

Please accept the enclosed page entitled "Abstract".

REMARKS


The amendments made herein serve to place the application in better form for prosecution by including the lineage of the application as well as by meeting the requirement for inclusion of an abstract on a separate sheet.

No new matter is added. The amendments to the claims find support throughout the specification.

An early and favorable examination on the merits is respectfully requested.

Respectfully submitted,
FROMMER LAWRENCE & HAUG LLP

By:


Thomas J. Kowalski
Reg. No. 32,147
(212) 588-0800

20220920 9/80300T